Relapsed or refractory large B-cell lymphoma (r/r LBCL)
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. DLBCL displays significant heterogeneity in biological characteristics, so patients have different treatment outcomes due to their different responses to treatment. 60% of patients can achieve longer survival benefits from 1L treatment, but the others still face challenges of relapsed or refractory lymphoma treatment. Their living conditions need to be improved.
The RELIANCE study (NCT04089215) is a prospective, single‑arm, multicenter, pivotal phase I/II study. In the LBCL cohort of the RELIANCE1 study2,3, 59 patients with r/r LBCL who failed at least two lines of therapy were treated with relma-cel.
- Deep response: Relma‑cel achieved a best complete response rate (CRR) of 70.4% in Chinese LBCL patients treated with ≥3 lines of therapy&,1
- Durable benefit: Median PFS and DOR with relma‑cel were 8.8 and 23.3 months, respectively&,1,4; the 4‑year overall survival (OS) rate in relma‑cel‑treated patients was 66.7%, demonstrating “curative” potential3,5
- Tolerable safety: No grade ≥3 CRS or neurologic events occurred with relma‑cel&,1
Note: The data above comes from the RELIANCE study, individual patient may have different results of treatment in the clinical practice based on multiple factors, including physical condition, disease status, T cell function and so on. It is recommended that you can consult the healthcare professionals if you have specific questions.
&Data from the cohort receiving the 100×106
1. Ying ZT, et al. Cancer Med 2021; 10(3):999-1011.
2. Z. Ying et al. Cytotherapy 2023; 1-9
3. Yang HY, et al. ASCO Abstract e19001.
4. Ying Z,et al. 2022 Abstract 7529
5. Data on file of JW Therapeutics.